Research programme: sandalwood album oil therapeutics - Santalis Pharmaceuticals
Latest Information Update: 28 May 2021
At a glance
- Originator Santalis Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 May 2021 No recent reports of development identified for research development in Cancer in Australia
- 28 May 2021 No recent reports of development identified for research development in Cancer in USA
- 18 Apr 2017 Santalis Pharmaceuticals has patent protection for ssandalwood album oil for treatment of Cancer in Australia